Hadasit Bio Holdings Ltd. (HBL)

About

Portfolio · 1

Enlivex

A clinical-stage macrophage reprogramming immunotherapy company developing Allocetra™ for inflammatory diseases and operating a prediction markets treasury.

Led ★ 1 round $8.0M committed Latest: 2017-09

Q&A

What is Hadasit Bio Holdings Ltd. (HBL)'s primary investment focus?

Hadasit Bio Holdings Ltd. (HBL) is a publicly traded Israeli investment fund focused on early-stage biotech companies, primarily those originating from Hadassah University Hospital.

What is the relationship between Hadasit Bio Holdings Ltd. (HBL) and Hadassah University Hospital?

Hadasit Bio Holdings Ltd. (HBL) is a subsidiary of Hadasit Ltd., the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. HBL was founded to allow public participation in biotechnology innovations derived from Hadassah University Hospital's intellectual property and R&D capabilities.

What stages of investment does Hadasit Bio Holdings Ltd. (HBL) typically engage in?

Hadasit Bio Holdings Ltd. (HBL) invests in Seed, Series A, Series B, Venture - Series Unknown, and R&D stages.

What are Hadasit Bio Holdings Ltd. (HBL)'s preferred sectors for investment?

Hadasit Bio Holdings Ltd. (HBL) prefers sectors such as Biotechnology, Medical, Health Care, Pharmaceutical, and Biopharma.

What is Hadasit Bio Holdings Ltd. (HBL)'s investment thesis regarding clinical trials?

HBL focuses on funding the preparation for and execution of Phase I and preparation for Phase II by its portfolio companies, which are based on IP generated by Hadassah University Hospital.

Where is Hadasit Bio Holdings Ltd. (HBL) headquartered?

Hadasit Bio Holdings Ltd. (HBL) is headquartered in Jerusalem, Israel.

When was Hadasit Bio Holdings Ltd. (HBL) founded?

Hadasit Bio Holdings Ltd. (HBL) was founded in September 2005.